Valneva

Valneva Insider Lock-Up Expiry Raises Selling Risk as Stock Hovers Near Low

Brett Shapiro - June 29, 2026

Valneva’s Two-Shot Hope: Lyme Vaccine Filing and Shigella Data Could Break the Slide

angelina - June 14, 2026

Valneva’s Double Blow: Technical Support Shatters as Cost-Cutting Deepens Ahead of Critical Vaccine Filing

Brett Shapiro - June 11, 2026

Valneva’s Bleak Q1: Revenue Halved, Net Loss Tripled, and the Only Lifeline Is a Lyme Vaccine Filing Due This Autumn

kashif hafeez - June 7, 2026

Valneva Faces a Test of Resilience as Legal Clouds and Analyst Skepticism Gather

April 26, 2026

Valneva’s Statistical Hurdle Casts Shadow Over Promising Lyme Disease Vaccine

angelina - March 26, 2026

Valneva’s Future Hinges on Lyme Disease Vaccine Candidate

angelina - March 21, 2026

Valneva Shares: A Financial Transformation Unfolds

November 20, 2025

Valneva Shares Plunge on Revenue Forecast Downgrade

kashif hafeez - November 19, 2025

Valneva Shares Face Critical Earnings Test Amid Bleak Projections

Brett Shapiro - November 12, 2025